Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Journal
The Lancet. Oncology
Journal Volume
24
Journal Volume
24
Journal Issue
12
Journal Issue
12
Start Page
1399
End Page
1410
ISSN
1470-2045
Date Issued
2023-12
Author(s)
Llovet, Josep M
Kudo, Masatoshi
Merle, Philippe
Meyer, Tim
Qin, Shukui
Ikeda, Masafumi
Xu, Ruocai
Edeline, Julien
Ryoo, Baek-Yeol
Ren, Zhenggang
Masi, Gianluca
Kwiatkowski, Mariusz
Lim, Ho Yeong
Kim, Jee Hyun
Breder, Valeriy
Kumada, Hiromitsu
Galle, Peter R
Kaneko, Shuichi
Wang, Anran
Mody, Kalgi
Dutcus, Corina
Dubrovsky, Leonid
Siegel, Abby B
Finn, Richard S
et al.
Abstract
Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma.
SDGs
Type
journal article